| Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ... The lancet oncology 18 (12), 1688-1700, 2017 | 644 | 2017 |
| Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 … A Chan, S Delaloge, FA Holmes, B Moy, H Iwata, VJ Harvey, NJ Robert, ... The Lancet Oncology 17 (3), 367-377, 2016 | 634 | 2016 |
| MYC and MCL1 cooperatively promote chemotherapy-resistant breast cancer stem cells via regulation of mitochondrial oxidative phosphorylation K Lee, JM Giltnane, JM Balko, LJ Schwarz, AL Guerrero-Zotano, ... Cell metabolism 26 (4), 633-647. e7, 2017 | 513 | 2017 |
| PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment A Guerrero-Zotano, IA Mayer, CL Arteaga Cancer and Metastasis Reviews 35, 515-524, 2016 | 371 | 2016 |
| Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer L Formisano, Y Lu, A Servetto, AB Hanker, VM Jansen, JA Bauer, ... Nature communications 10 (1), 1373, 2019 | 306 | 2019 |
| Intrinsic subtypes and gene expression profiles in primary and metastatic breast cancer JM Cejalvo, E Martínez de Dueñas, P Galván, S García-Recio, ... Cancer research 77 (9), 2213-2221, 2017 | 235 | 2017 |
| Association of FGFR1 with ERα maintains ligand-independent ER transcription and mediates resistance to estrogen deprivation in ER+ breast cancer L Formisano, KM Stauffer, CD Young, NE Bhola, AL Guerrero-Zotano, ... Clinical Cancer Research 23 (20), 6138-6150, 2017 | 127 | 2017 |
| Report on computational assessment of tumor infiltrating lymphocytes from the International Immuno-Oncology Biomarker Working Group M Amgad, ES Stovgaard, E Balslev, J Thagaard, W Chen, S Dudgeon, ... NPJ breast cancer 6 (1), 16, 2020 | 122 | 2020 |
| Phase III trial of adjuvant capecitabine after standard neo-/adjuvant chemotherapy in patients with early triple-negative breast cancer (GEICAM/2003-11_CIBOMA/2004-01) A Lluch, CH Barrios, L Torrecillas, M Ruiz-Borrego, J Bines, J Segalla, ... Journal of clinical oncology 38 (3), 203-213, 2020 | 117 | 2020 |
| Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant … M Martin, C Zielinski, M Ruiz-Borrego, E Carrasco, N Turner, EM Ciruelos, ... Annals of oncology 32 (4), 488-499, 2021 | 94 | 2021 |
| A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole Z Garcia-Casado, A Guerrero-Zotano, A Llombart-Cussac, A Calatrava, ... BMC cancer 10, 1-11, 2010 | 93 | 2010 |
| Genomic and transcriptomic analyses of breast cancer primaries and matched metastases in AURORA, the Breast International Group (BIG) molecular screening initiative P Aftimos, M Oliveira, A Irrthum, D Fumagalli, C Sotiriou, EN Gal-Yam, ... Cancer discovery 11 (11), 2796-2811, 2021 | 92 | 2021 |
| Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study EM de Dueñas, AL Hernández, ÁG Zotano, RMP Carrión, ... Breast cancer research and treatment 143, 507-515, 2014 | 90 | 2014 |
| A review of the treatment of endocrine responsive metastatic breast cancer in postmenopausal women F Cardoso, J Bischoff, E Brain, ÁG Zotano, HJ Lück, VC Tjan-Heijnen, ... Cancer treatment reviews 39 (5), 457-465, 2013 | 86 | 2013 |
| Phase II trial with letrozole to maximum response as primary systemic therapy in postmenopausal patients with ER/PgR [+] operable breast cancer A Llombart-Cussac, Á Guerrero, A Galán, V Carañana, E Buch, ... Clinical and Translational Oncology 14, 125-131, 2012 | 76 | 2012 |
| Hyperactivation of TORC1 drives resistance to the pan-HER tyrosine kinase inhibitor neratinib in HER2-mutant cancers DR Sudhan, A Guerrero-Zotano, H Won, PG Ericsson, A Servetto, ... Cancer cell 37 (2), 183-199. e5, 2020 | 48 | 2020 |
| Incidence and predictors of ovarian function recovery (OFR) in breast cancer (BC) patients with chemotherapy-induced amenorrhea (CIA) who switched from tamoxifen to exemestane A Guerrero, J Gavila, E Folkerd, B Ortiz, F Martínez, A García, MA Climent, ... Annals of oncology 24 (3), 674-679, 2013 | 42 | 2013 |
| Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer J Rodon, A Pérez-Fidalgo, IE Krop, H Burris, A Guerrero-Zotano, ... Cancer chemotherapy and pharmacology 82, 285-298, 2018 | 41 | 2018 |
| Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers … DR Sudhan, LJ Schwarz, A Guerrero-Zotano, L Formisano, MJ Nixon, ... Clinical Cancer Research 25 (2), 771-783, 2019 | 40 | 2019 |
| An ERBB1-3 neutralizing antibody mixture with high activity against drug-resistant HER2+ breast cancers with ERBB ligand overexpression LJ Schwarz, KE Hutchinson, BN Rexer, MV Estrada, PI Gonzalez Ericsson, ... JNCI: Journal of the National Cancer Institute 109 (11), djx065, 2017 | 39 | 2017 |
